Clorox Gestion
Gestion contrôle des critères 4/4
Le PDG Clorox est Linda Rendle, nommé en Sep2020, a un mandat de 5.67 ans. La rémunération annuelle totale est $ 13.33M, composée du salaire de 9.8% et des bonus 90.2%, y compris les actions et options de la société. détient directement 0.025% des actions de la société, d'une valeur de $ 2.88M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.7 ans et 5.7 ans.
Informations clés
Linda Rendle
Directeur général
US$13.3m
Rémunération totale
| Pourcentage du salaire du PDG | 9.81% |
| Durée du mandat du directeur général | 5.7yrs |
| Propriété du PDG | 0.03% |
| Durée moyenne d'occupation des postes de direction | 4.7yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.7yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • May 14
CLX: GOJO Integration And Need Based Focus Will Support Long Term Earnings
Analysts have trimmed the blended fair value estimate for Clorox to about $144 from roughly $155, as a series of firms cut price targets, citing refreshed views on growth, margins, and future P/E multiples following recent research updates. Analyst Commentary Recent research has been dominated by cuts to fair value estimates and price targets, yet there are still some constructive signals in the commentary that matter if you are focused on Clorox's long term setup rather than just near term P/E compression.
Mise à jour du récit • Apr 29
CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple
Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.Seeking Alpha • Apr 28
Clorox: Reduced Complexity Paves The Way For Multiple Expansion
Summary Clorox is attractively valued after underperformance, offering a 5% dividend yield and normalization post-cyber attack and ERP disruptions. The recent Purell (GOJO) acquisition is set to be accretive to EBITDA and EPS by FY27, supporting top-line growth above the company's long-term algorithm. CLX trades at 14.5x FY27 EPS, with double-digit earnings growth and room for multiple expansion relative to peers, setting up 20% upside potential. Risks include high customer concentration, private label competition, and consumer value-seeking behavior, but strong cash flow supports deleveraging and dividend sustainability. Read the full article on Seeking Alpha
Mise à jour du récit • Apr 15
CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power
Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.Mise à jour du récit • Mar 31
CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power
Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.Mise à jour du récit • Mar 17
CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook
Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.Mise à jour du récit • Mar 03
CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power
Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.Mise à jour du récit • Feb 17
CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E
The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.Mise à jour du récit • Feb 03
CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple
Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.Mise à jour du récit • Jan 20
CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating
Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.Mise à jour du récit • Jan 05
CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating
Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.Mise à jour du récit • Dec 20
CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook
Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.Mise à jour du récit • Dec 05
CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery
Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.Mise à jour du récit • Nov 21
CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026
Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.Article d’analyse • Nov 12
Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet
Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...Article d’analyse • Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues
The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...Mise à jour du récit • Nov 06
CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026
Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.Mise à jour du récit • Oct 23
Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook
Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.Mise à jour du récit • Oct 09
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.Mise à jour du récit • Aug 27
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.Article d’analyse • Aug 04
Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24
The Clorox Company ( NYSE:CLX ) will increase its dividend on the 29th of August to $1.24, which is 1.6% higher than...Article d’analyse • Aug 02
Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...Article d’analyse • Jul 16
Returns On Capital At Clorox (NYSE:CLX) Have Stalled
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Mar 29
Clorox: Reviving From Cyberattack; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Clorox: A Wonderful Business I Would Like To Own At A Lower Price
Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking AlphaSeeking Alpha • Nov 26
The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals
Summary I rate The Clorox Company a hold due to its volatile financial performance and current stock trading above fair value. Despite revenue fluctuations, Clorox has strong brand recognition and promising growth potential, with 80% of sales from top-ranked products. The company's resilience is evident through consistent dividends, high ROE, ROCE, and positive EVA, indicating shareholder value creation. Clorox's recovery is marked by significant YoY growth in revenue, net income, and operational efficiency, showcasing potential for future growth. Read the full article on Seeking AlphaAnalyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$756m |
| Dec 31 2025 | n/a | n/a | US$755m |
| Sep 30 2025 | n/a | n/a | US$791m |
| Jun 30 2025 | US$13m | US$1m | US$810m |
| Mar 31 2025 | n/a | n/a | US$694m |
| Dec 31 2024 | n/a | n/a | US$457m |
| Sep 30 2024 | n/a | n/a | US$357m |
| Jun 30 2024 | US$13m | US$1m | US$280m |
| Mar 31 2024 | n/a | n/a | US$240m |
| Dec 31 2023 | n/a | n/a | US$80m |
| Sep 30 2023 | n/a | n/a | US$86m |
| Jun 30 2023 | US$12m | US$1m | US$149m |
| Mar 31 2023 | n/a | n/a | US$74m |
| Dec 31 2022 | n/a | n/a | US$435m |
| Sep 30 2022 | n/a | n/a | US$405m |
| Jun 30 2022 | US$9m | US$1m | US$462m |
| Mar 31 2022 | n/a | n/a | US$458m |
| Dec 31 2021 | n/a | n/a | US$247m |
| Sep 30 2021 | n/a | n/a | US$437m |
| Jun 30 2021 | US$8m | US$1m | US$710m |
| Mar 31 2021 | n/a | n/a | US$923m |
| Dec 31 2020 | n/a | n/a | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | US$2m | US$524k | US$939m |
| Mar 31 2020 | n/a | n/a | US$870m |
| Dec 31 2019 | n/a | n/a | US$816m |
| Sep 30 2019 | n/a | n/a | US$813m |
| Jun 30 2019 | US$2m | US$436k | US$820m |
Rémunération vs marché: La rémunération totale de Linda ($USD 13.33M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 14.80M ).
Rémunération et revenus: La rémunération de Linda a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Linda Rendle (46 yo)
5.7yrs
Titularisation
US$13,333,032
Compensation
Ms. Linda J. Rendle serves as Independent Director at Visa Inc. since January 23,2020. She serves as Chief Executive Officer and Director of The Clorox Company since September 14 2020 & serves as January 1...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 5.7yrs | US$13.33m | 0.025% $ 2.9m | |
| Executive VP & CFO | 1.1yrs | US$2.62m | 0.0093% $ 1.1m | |
| Executive VP and Group President of Health & Hygiene | 4.7yrs | US$4.37m | 0.0090% $ 1.0m | |
| Executive VP and Group President of Care & Connection | 1.8yrs | US$10.07m | 0.0029% $ 331.7k | |
| VP, Chief Accounting Officer & Corporate Controller | 5yrs | pas de données | 0.0036% $ 410.3k | |
| Senior VP and Chief Information & Data Officer | 5.9yrs | pas de données | pas de données | |
| Executive VP & Chief Administrative Officer | 1.1yrs | US$3.54m | 0.019% $ 2.2m | |
| Vice President of Investor Relations | no data | pas de données | pas de données | |
| Executive VP | 20.8yrs | US$3.45m | 0.013% $ 1.5m | |
| Senior VP & Chief Marketing Officer | 4.2yrs | pas de données | pas de données | |
| Chief Diversity Officer | 19.9yrs | pas de données | pas de données | |
| Executive VP and Executive Chief of Staff | 4.2yrs | US$3.56m | 0.0066% $ 752.3k |
4.7yrs
Durée moyenne de l'emploi
51.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de CLX est considérée comme expérimentée (ancienneté moyenne 4.7 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 5.7yrs | US$13.33m | 0.025% $ 2.9m | |
| Independent Director | 9.8yrs | US$270.00k | 0.00050% $ 57.0k | |
| Independent Director | 10.8yrs | US$292.18k | 0.00070% $ 79.8k | |
| Independent Director | 1yr | US$12.40k | pas de données | |
| Independent Director | 12.8yrs | US$285.00k | pas de données | |
| Lead Independent Director | 7.8yrs | US$370.00k | pas de données | |
| Independent Director | 9.3yrs | US$272.25k | pas de données | |
| Independent Director | 1.5yrs | US$149.80k | 0.015% $ 1.7m | |
| Independent Director | 1.5yrs | US$146.98k | pas de données | |
| Independent Director | 4yrs | US$270.00k | pas de données | |
| Independent Director | 4yrs | US$270.00k | pas de données |
5.7yrs
Durée moyenne de l'emploi
61yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de CLX sont considérés comme expérimentés (ancienneté moyenne 5.7 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 04:05 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
The Clorox Company est couverte par 34 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| John Staszak | Argus Research Company |
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |